Distance-Based All-In-One Immunodevice for Point-of-Care Monitoring of Cytokine Interleukin‑6

Journal article


Authors/Editors


Strategic Research Themes


Publication Details

Author listKawin Khachornsakkul, Wijitar Dungchai and Nicole Pamme

PublisherAmerican Chemical Society

Publication year2022

JournalACS Sensors (23793694)

Volume numberึ7

Issue number8

Start page2410

End page2419

Number of pages10

ISSN23793694

eISSN2379-3694

URLhttps://pubs.acs.org/doi/10.1021/acssensors.2c01122


View in Web of Science | View on publisher site | View citing articles in Web of Science


Abstract

We report the development of a distance-based paper analytical device combined with a hydrophilic bridge valve (BdPAD) as a quantitative immunoassay method to monitor human interleukin-6 (IL-6) in human samples. Our device design features (i) a circular sample inlet zone, (ii) a circular capture zone with immobilized anti-IL-6 (anti-Ab1), and (iii) a detection zone channel coated with methylene blue (MB). Two hydrophilic valves are positioned between these three zones. IL-6 levels were determined quantitatively by measuring the extent of degradation of MB to a colorless product along the length of the detection zone channel. Following method optimization, we obtained a linear range from 0.05 to 25.0 pg/mL (R2 = 0.9995) and a detection limit (LOD) of 0.05 pg/mL by the naked-eye readout. This is directly within the clinically relevant range. The system does not require any external instrumentation, and the bridge valves can be easily connected and disconnected by a minimally trained operator. The total analysis time is 35 min, significantly reduced from a typical ELISA assay, which takes around 1 h since the B-dPAD workflow circumvents washing steps. The device was tested for IL-6 quantification in human saliva and urine samples of volunteers, with no significant difference found between our method and the standard clinical laboratory method at 95% confidence levels. Recoveries ranged from 98 to 105% with the highest standard deviation at 3.9%. Our B-dPAD immunodevice is therefore a promising approach for rapid IL6 monitoring in the context of point-of-care diagnostics and analysis in resource-limited settings.


Keywords

No matching items found.


Last updated on 2023-20-09 at 07:37